American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31.

Authors

Robert P Perrillo¹, Robert Gish², Yngve T Falck-Ytter³

Affiliations

¹ Hepatology Division, Baylor University Medical Center, Department of Medicine, University of Texas Southwestern, Dallas, Texas.
² Division of Gastroenterology and Hepatology, Department of Medicine,Stanford University, Palo Alto, California; Hepatitis B Foundation, Doylestown, Pennsylvania.
³ Division of Gastroenterology and Hepatology, Department of Medicine, Case and VA Medical Center, Case Western Reserve University, Cleveland, Ohio.

PMID: 25447852
DOI: 10.1053/j.gastro.2014.10.038

No abstract available

Publication types

Meta-Analysis
Review

MeSH terms

Antiviral Agents / therapeutic use*
Biomarkers / blood
DNA, Viral / blood
Gastroenterology
Hepatitis B / diagnosis
Hepatitis B / drug therapy*
Hepatitis B / immunology
Hepatitis B / prevention & control*
Hepatitis B / virology
Hepatitis B Antibodies / blood
Hepatitis B Surface Antigens / blood
Hepatitis B virus / drug effects*
Hepatitis B virus / genetics
Hepatitis B virus / immunology
Hepatitis B virus / pathogenicity
Humans
Immunosuppressive Agents / adverse effects*
Recurrence
Risk Factors
Societies, Medical
Treatment Outcome
Viral Load
Virus Activation / drug effects*

Substances

Antiviral Agents
Biomarkers
DNA, Viral
Hepatitis B Antibodies
Hepatitis B Surface Antigens
Immunosuppressive Agents